SCHEMBL3564009

SCHEMBL3564009

CN(C)S(=O)(=O)Nc1cccc(-c2cccc(-c3nc(-c4ccc(C(F)(F)F)cc4)cc(C(F)(F)F)n3)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.57
FLT3 P36888 1/20 0.57
KIF11 P52732 2/20 0.53
PFKFB3 Q16875 1/20 0.48
ERAP1 Q9NZ08 1/20 0.47
SYK P43405 1/20 0.44
PTGS2 P35354 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
S1PR4 O95977 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
S1PR1 P21453 1/20 0.42
SDHB P21912 1/20 0.42
MAPK1 P28482 1/20 0.42
STAT3 P40763 1/20 0.42
STAT1 P42224 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3565704 0.88 KIF11 (0.70) KIF11PFKFB3ERAP1SYKPTGS2
SCHEMBL3567515 0.86 KIF11 (0.53) KIF11PFKFB3ERAP1
SCHEMBL3568019 0.79 SDHB (0.54) PTGS2MEN1KMT2AS1PR4LMNA
SCHEMBL3568722 0.77 PTGES2 (0.48) KIF11SYKMEN1KMT2AS1PR4
SCHEMBL3561893 0.77
SCHEMBL3556992 0.77 MEN1 (0.45) MEN1KMT2AS1PR4LMNATP53
SCHEMBL3562431 0.77 PFKFB3 (0.47) PFKFB3MEN1KMT2AS1PR4LMNA
SCHEMBL3570532 0.76 ALDH1A1 (0.44) MEN1KMT2AS1PR4LMNATP53
SCHEMBL3559328 0.75
SCHEMBL3565084 0.75 KIF11 (0.53) NTRK1FLT3KIF11PFKFB3ERAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP claimed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US claimed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 NTRK1 1899/4885FLT3 612/4885KIF11 3845/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 NTRK1 1173/4885FLT3 629/4885KIF11 3339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.